Perspective Therapeutics, Inc. (CATX)
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
$0.79-9.40%
Close 2026-11-05 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · CATX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -58.0% |
| Our one-year growth estimate | diamond | -93.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 35.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 29 industry peers
CATX — earnings miss
Dated 2026-03-16
The information furnished pursuant to this Item 2.02, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any of the Company’s filings with the Securities and Exchange Commission under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after…
Why it matters: The FDA meeting will shape the path to the first Phase 3 study. A clear path would support the program's next step.
Supportive ifThe company reports FDA alignment on the Phase 3 plan and starts site activation around year-end 2026.
Worry ifThe FDA asks for more studies or a changed plan, and site activation moves past year-end 2026.
Why it matters: The site is part of the plan to supply clinical studies and future operations. A delay could strain that plan.
Watch forThe company reports Chicago construction complete in early 2027 and gives a start date for the site.
Also watch forConstruction is still incomplete after early 2027, or the company reports a delay to the site start.
Why it matters: The September deal adds Merck to the company's clinical work. Named trial steps or supply details would show how the partnership advances.
Supportive ifA company filing or release names a trial start, patient dosing, or a supply step under the Merck deal.
Worry ifThe company names no trial or supply step in its next two quarterly updates, or reports a delay.
Why it matters: The melanoma study has early results from seven patients on the 3.0 mCi solo dose. More follow-up can show if those responses hold.
Watch forLate-2026 data confirm tumor responses in the seven patients treated with 3.0 mCi alone.
Also watch forLate-2026 scans show no confirmed responses in those seven patients, or show new serious safety issues.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$262 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $871 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,460 loss on $10,000 · 84.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Longer treatment follow-up will test whether the safety record holds. Kidney effects matter because they can limit ongoing treatment.
Worry ifNew reports show more than 2 of 68 patients with Grade 3 kidney events, or any Grade 4 or 5 event.
Less concerning ifLonger follow-up reports no new Grade 3 kidney events and no Grade 4 or 5 events.